Therapeutic effect of Qinggan Huayu granule on diethylnitrosamine-induced primary liver cancer rats
-
摘要: 目的:研究清肝化瘀颗粒对二乙基亚硝胺(DEN)所致原发性肝癌大鼠的治疗作用。方法:将162只雄性SD大鼠随机平均分为模型组、肝复乐组、化疗药组及清肝化瘀颗粒低、中、高剂量组。应用DEN腹腔注射法制备原发性肝癌大鼠模型,分别给予生理盐水10 mL/(kg·d)灌胃,肝复乐组0.94 g/(kg·d)灌胃,氟尿嘧啶注射液50 mg/(kg·w)腹腔注射,清肝化瘀颗粒0.47、0.93、1.86 g/(kg·d)灌胃,连续给药8周。末次给药后各组随机选取6只大鼠解剖,观察肝脏成癌情况,检测血清肝功能。结果:清肝化瘀颗粒组大鼠的肝脏大体与病理组织学癌变程度均较模型组减轻明显;清肝化瘀颗粒组肝指数较模型组显著降低,中、高剂量组肝脏表面癌结节数显著低于模型组(P<0.05);清肝化瘀颗粒可显著降低血清TBIL、GGT、AFU水平(P<0.05或P<0.01),且中、高剂量组以及化疗药组分别具有显著降低血清ALP、AST水平的作用(P<0.05)。结论:清肝化瘀颗粒能够有效缓解DEN诱导原发性肝癌大鼠的肝损伤,改善其肝功能。Abstract: Objective: To observe the therapeutic effect of Qinggan Huayu granule on primary liver cancer(PLC) rats induced by diethylnitrosamine(DEN).Methods: One hundred and sixty-two SD male rats were randomly divided into model group, Ganfule group, and chemotherapeutic group, low-group, medium-group, and high-dose of Qinggan Huayu granule groups. Rat models of primary liver cancer were prepared by DEN intraperitoneal injection method, and saline at does of 10 mL/(kg·d), Qinggan Huayu granule at does of 0.47 g/(kg·d), 0.93 g/(kg·d), 1.86 g/(kg·d), Ganfule at does of 0.94 g/(kg·d) for gavage and fluorouracil 50 mg/(kg·w) intraperitoneal injection were given for 8 weeks. After the last administration, six rats was randomly selected from each group for dissection toobserve the incidence of liver cancer and detect serum liver function.Results: The degree of gross and histopathological of liver cancer rats of Qinggan Huayu granule group were significantly reduced compared with that of model group. The liver index of Qinggan Huayu granule group was significantly lower than the model group, and the number of carcinoma nodules on the liver surface of the medium and high dose groups was significantly lower than that of the model group(P<0.05). The serum TBIL, GGT and AFU levels were significantly reduced by Qinggan Huayu granule(P<0.05 or P<0.01), in addition, the serum ALP and AST levels could be significantly reduced by medium-dose, high-dose of Qinggan Huayu granule groups and chemotherapeutic group respectively(P<0.05).Conclusion: Qinggan Huayu granule can effectively relieve the liver injury of DEN-induced primary liver cancer in rats and improve liver function.
-
Key words:
- primary liver cancer /
- diethylnitrosamine /
- Qinggan Huayu granule /
- liver function
-
-
[1] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):1-31.
[2] 周俭,肖永胜.肝癌的转化医学研究——从基础到临床[J].中国普通外科杂志,2016,25(1):1-5.
[3] 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):1419-1431.
[4] 卢舜,王熙,周小康.温肾健脾法治疗肝癌靶向药物索拉非尼所致腹泻的临床研究[J].中国中西医结合消化杂志,2020,28(3):177-179.
[5] 吴玉潇,盛庆寿.中医药治疗原发性肝癌的研究进展[J].广西医学,2020,42(4):483-485.
[6] Woojin K,Won L.Traditional herbal medicine as adjunctive ther-apy for breast cancer;A systematic review[J].Complement Therap Med,2015,23(4):626-632.
[7] 李杨,陈晶.消癌解毒方通过内质网应激诱导肝癌HepG2细胞凋亡的研究[J].中国中西医结合消化杂志,2020,28(6):408-412.
[8] 姚树坤,殷飞,王娜.清肝化瘀方药对原发性肝癌患者的疗效及对细胞免疫功能的影响[J].临床荟萃,2006,21(18):1300-1302.
[9] 王永中,姚树坤,高立明,等.清肝化瘀口服液对原发性肝癌介入治疗后免疫功能影响的临床研究[J].中国老年学,2008,28(8):770-772.
[10] 宋威江.清肝化瘀颗粒对二乙基亚硝胺致大鼠原发性肝癌抑制作用及机制研究[D].北京:北京中医药大学,2016.
[11] Tasaki M,Kuroiwa Y,Inoue T,et al.Lack of nrf2 results inprogression of proliferative lesions to neoplasms induced by long-termexposure to non-genotoxic hepatocarcinogens involving oxidativestress[J].Exp Toxicol Pathol,2014,66(1):19-26.
[12] 宋亚刚,李艳,苗明三.基于原发性肝癌临床病症特点的动物模型分析[J].中华中医药杂志,2018,33(12):5563-5567.
[13] Yang FC,Zheng SS,Jiang TA.Modified hepatocarcinomamodel in rats[J].Natl Med J China,2004,84(23):2018-2019.
[14] 邓茹芸.原发性肝癌模型的改良与清肝化瘀颗粒急性毒理学研究[D].北京:北京中医药大学,2019.
[15] 柯昌征,王传敏,康健,等.AFP、CA19-9、SF、AFU联合肝脏MRI诊断原发性肝癌的效能分析[J].标记免疫分析与临床,2018,25(5):684-688.
[16] 李宏斌,石珏,李娜.原发性肝癌患者PIVKA-Ⅱ、A-FU、HIF-1α的表达及其临床意义[J].医学临床研究,2019,36(2):360-362.
[17] 周宁.血清GGT、AFP、ALP、AFU联合检测在诊断原发性肝癌中的应用价值[J].当代医药论丛,2019,17(6):150-151.
-
计量
- 文章访问数: 446
- PDF下载数: 333
- 施引文献: 0
下载: